HomeNewsBusinessMarketsRBI could create TARP-like structure to avoid another Franklin Templeton episode: Gaurav Garg

RBI could create TARP-like structure to avoid another Franklin Templeton episode: Gaurav Garg

The selling pressure from the outbreak of COVID-19 with illiquid markets and negative sentiments on the street due to the economic slowdown left Franklin Templeton to close the scheme.

April 27, 2020 / 09:52 IST
Story continues below Advertisement

The RBI may have to intervene by creating some sort of TARP-like structure. The SEBI will have to stretch its limit for loans taken by debt funds to allow for such a scheme, and if the debt market is to unfreeze, it would require considerable care of the RBI and SEBI, Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor, said in an interview with Moneycontrol’s Kshitij Anand.

Edited excerpt:

Story continues below Advertisement

Q) The Nifty50 fell by about 1% in the week gone by. What are your views on the market?

A) Investors are expecting another stimulus packages especially focusing on the unorganized sector. On Friday, the Nifty50 opened with a gap-down and attempted to recover in the second half of the trading session, which resulted in a closing downside by 1.71 percent at 9154.40.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show